Literature DB >> 33348975

HSA_CIRC_0004050 on proliferation and apoptosis of A549 cells through ERK/JNK signaling pathway.

Y Wang1, R K Zang1, Y N Du1.   

Abstract

The aim of this study was to screen the differentially expressed circular ribonucleic acid (circRNA) in non-small cell lung cancer (NSCLC) and explore its functional mechanism. Differentially expressed circRNAs in tumor tissues of NSCLC patients were detected via gene microarray and reverse transcriptionquantitative polymerase chain reaction (RT-qPCR). The associaton between their expressions and the clinical phenotypes was explored combined with clinical data. The effect of overexpression of hsa_circ_0004050 on the proliferation of A549 cells was detected via cell counting kit-8 (CCK-8) assay and CFSE assay. The effect of overexpression of hsa_circ_0004050 (human circular ribonucleic acid_0004050) on the apoptosis of A549 cells was detected using the Annexin V-FITC/PI kit. Then the direct-acting miRNAs of hsa_circ_0004050 were screened using bioinformatics software and luciferase reporter assay, and the direct targets of miR- 1233-3p were explored using bioinformatics software and luciferase reporter assay combined with RTqPCR and Western blotting. The effects of overexpression of miR-1233-3p or knockdown of dual specificity phosphatase 9 (DUSP9) on the cell proliferation and apoptosis affected by overexpression of hsa_circ_0004050 were detected. Western blotting was performed to detect the effects of hsa_circ_0004050 on the extracellular signal-regulated kinase (ERK)/c-Jun N-terminal kinase (JNK) signaling pathway. The expression of hsa_ circ_0004050 was significantly lower in tumor tissues than that in para-carcinoma tissues in NSCLC patients. The expression of hsa_circ_0004050 was significantly correlated with TNM stage, tumor size and lymph node metastasis. The results of survival analysis showed that the survival time of patients with a high expression of hsa_circ_0004050 was obviously prolonged. According to the results of phenotype assay, hsa_circ_0004050 could promote apoptosis and inhibit proliferation of A549 cells. In terms of its mechanism, hsa_circ_0004050 could markedly increase the protein expression of DUSP9 via targeting miR-1233-3p in A549 cells, thereby inhibiting the ERK/JNK signaling pathway. Hsa_circ_0004050 may serve as a potential therapeutic target for NSCLC or a biomarker for the diagnosis of NSCLC in the future. Copyright 2020 Biolife Sas. www.biolifesas.org.

Entities:  

Keywords:  A549 cell lines; ERK/JNK signaling pathway; apoptosis; cell proliferation; hsa_circ_0004050

Year:  2020        PMID: 33348975     DOI: 10.23812/20-543-A

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  5 in total

1.  [Research Progress in CircRNA and Radiotherapy Resistance of Non-small Cell Lung Cancer].

Authors:  Weilong Li; Shenglin Ma; Shirong Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-11-20

Review 2.  Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.

Authors:  Ying Liu; Xiang Ao; Wanpeng Yu; Yuan Zhang; Jianxun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-19       Impact factor: 8.886

Review 3.  DUSP9, a Dual-Specificity Phosphatase with a Key Role in Cell Biology and Human Diseases.

Authors:  Fatma Zohra Khoubai; Christophe F Grosset
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

4.  Circular RNA Eps15-homology domain containing protein 2 motivates proliferation, glycolysis but refrains autophagy in non-small cell lung cancer via crosstalk with microRNA-3186-3p and forkhead box K1.

Authors:  Fan Zhang; Tieying Zhang; ZiRan Zhao; Ying Ji; Yue Peng; Liang Zhao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Induction of ligustrazine apoptosis of A549 cells through activation of death receptor pathway.

Authors:  Wei Zheng; Jihua Yang; Juyi Wen; Junzhao Sun; Jing Wang; Xinhong Zhang; Xia Zhang; Xiangfei Zhao; Henghu Fang; Qi Zhu; Shanshan Wu; Zejun Lu; Heng Sun; Rugang Zhao; Siyuan Huai; Lipin Gao; Yongzhen Liu; Jingjiao Li; Gaowa Guan; Wei Yang; Yi Hu
Journal:  Transl Cancer Res       Date:  2022-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.